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Abdominal aortic calciﬁcation on lateral spine images
captured during bone density testing and late-life
dementia risk in older women: A prospective cohort
study
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Summary
Background Dementia after the age of 80 years (late-life) is increasingly common due to vascular and non-vascular
risk factors. Identifying individuals at higher risk of late-life dementia remains a global priority.
Methods In prospective study of 958 ambulant community-dwelling older women (≥70 years), lateral spine images
(LSI) captured in 1998 (baseline) from a bone density machine were used to assess abdominal aortic calcification
(AAC). AAC was classified into established categories (low, moderate and extensive). Cardiovascular risk factors and
apolipoprotein E (APOE) genotyping were evaluated. Incident 14.5-year late-life dementia was identified from linked
hospital and mortality records.
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Findings At baseline women were 75.0 § 2.6 years, 44.7% had low AAC, 36.4% had moderate AAC and 18.9% had
extensive AAC. Over 14.5- years, 150 (15.7%) women had a late-life dementia hospitalisation (n = 132) and/or death
(n = 58). Compared to those with low AAC, women with moderate and extensive AAC were more likely to suffer
late-life dementia hospitalisations (9.3%, 15.5%, 18.3%, respectively) and deaths (2.8%, 8.3%, 9.4%, respectively).
After adjustment for cardiovascular risk factors and APOE, women with moderate and extensive AAC had twice the
relative hazards of late-life dementia (moderate, aHR 2.03 95%CI 1.38−2.97; extensive, aHR 2.10 95%CI 1.33−3.32),
compared to women with low AAC.

Abbreviations: AAC, abdominal aortic calcification; AAC24, abdominal aortic calcification 24 scale scores; AUC, area under the
curve; AD, Alzheimer's disease; ASVD, atherosclerotic vascular disease; CAC, coronary artery calcification; CVD, cardiovascular disease; DXA, dual-energy X-ray absorptiometry; IDI, integrated discrimination improvement; LSI, lateral spine imaging; NRI, net
reclassification improvement; ROC, receiver operator characteristics; APOE, apolipoprotein E; FRS, Framingham General Cardiovascular Risk Scores
*Corresponding author at: Nutrition & Health Innovation Research Institute, School of Medical and Health Sciences, Edith Cowan
University, Level 3 Roayl Perth Hospital Medical Research Foundation Building, Rear of 50 Murray Street, Perth, WA, 6000, Australia.
E-mail address: marc.sim@ecu.edu.au (M. Sim).
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Interpretation In community-dwelling older women, those with more advanced AAC had higher risk of late-life
dementia, independent of cardiovascular risk factors and APOE genotype. Given the widespread use of bone density
testing, simultaneously capturing AAC information may be a novel, non-invasive, scalable approach to identify older
women at risk of late-life dementia.
Funding Kidney Health Australia, Healthway Health Promotion Foundation of Western Australia, Sir Charles
Gairdner Hospital Research Advisory Committee Grant, National Health and Medical Research Council of Australia.
Copyright Ó 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Keywords: Aging; Imaging; Vascular disease; Dementia; Epidemiology

Introduction
Research in context
Evidence before this study
Despite strong links between vascular disease and dementia risk there is a paucity of data on whether vascular calciﬁcation, and in particular extra-coronary vascular
calciﬁcations may be a marker of later life dementia risk.
The abdominal aorta is one of the ﬁrst sites where vascular
calciﬁcation is seen and abdominal aortic calciﬁcation (AAC)
is common in older men and women. To date, two studies
in middle-aged and older men and women have found the
presence and extent of AAC is associated with poorer cognitive function. To our knowledge no study has investigated
the association between AAC and dementia risk.
Added value of this study
Abdominal aortic calciﬁcation assessed on images from
bone density machines identiﬁes older women at a
higher risk of late-life dementia, independent of other
cardiovascular risk factors and APOE genotype. This
study suggests that capturing these lateral spine images
at the time of bone density testing may be an easy and
cost-effective way to identify women at higher risk of
developing late-life dementia.
Implications of all the available evidence
Vascular brain aging is increasingly being recognised
as a major driver of dementias, particularly late-life
dementia. Screening for a stable marker of advanced
vascular disease, abdominal aortic calciﬁcation at the
time of bone density testing may be a promising
approach to identify older women at higher risk of
cognitive decline and developing late-life dementia.
Early identiﬁcation may provide a window of opportunity to enable dietary, lifestyle and cardiovascular
risk management modiﬁcations to prevent disease
progression.

2

Dementia, in particular Alzheimer’s disease (AD), is recognised as having an extended asymptomatic prodromal
period of up to 20 years, characterised by gradual accumulation of neuropathological disease processes.1 This transitional phase provides a target for the implementation of
interventions before the onset of clinically significant
impairment which typically signals irreversible neurodegeneration. However, identifying people at high risk of
developing dementia during this preclinical phase remains
challenging and is a global priority. It is increasingly recognised that a substantial overlap between cardiovascular disease and both vascular dementia and AD exists with many
shared modifiable risk factors such as hypertension, obesity, smoking, and hypercholesterolaemia.2 Putative mechanisms underlying the association between vascular factors
and neurocognitive health include: small vessel disease (e.
g. microinfarcts and axonal pathology),3 regional hypo-perfusion,4 atherosclerosis5 and arteriosclerosis.6 Noteworthy,
abdominal aortic calcification (AAC) is a stable marker of
generalised advanced atherosclerosis,7 with associated
blood vessel stiffening resulting in higher pressures being
transmitted into small vessels in other organs such as the
brain leading to end-organ damage.8
Bone density testing with dual-energy X-ray absorptiometry machines (DXA) are widely used in osteoporosis
screening. These DXA machines can also easily and rapidly capture lateral thoracolumbar spine images at a
fraction of the cost and radiation exposure of standard
thoracolumbar radiographs to detect vertebral fractures.
These lateral spine images (LSI) can also be used to
identify and semi-quantify AAC using the 24-point Kaupilla scale (AAC24).9 The presence and extent of AAC is
associated with coronary artery calcifications10 and
carotid atherosclerosis.11 Furthermore, the presence and
extent of AAC is associated with substantially higher
cardiovascular risk and poorer long-term prognosis in
older men and women.12
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We therefore hypothesised that AAC assessed on
images captured using widely available bone density
machines would be a stable marker of accumulated vascular damage and as such associated with higher risk of
late-life dementia, independent of established CVD risk
factors and apolipoprotein E (APOE) genotype.

Materials and methods
Study population
Ambulant community-dwelling older Australian
women (≥70 years) were recruited to a five-year prospective, randomized, controlled trial of oral calcium
supplements to prevent osteoporotic fractures commencing in 1998.13 Women had an expected survival
beyond five-years, were ambulant, and not receiving any
medication (including hormone replacement therapy)
known to affect bone metabolism. Baseline disease burden and medications were comparable between study
participants and the general population of similar age,
albeit a higher socio-economic status.13 Over five-years,
participants received 1.2 g of elemental calcium (calcium carbonate) daily or a matching placebo. Upon
completion, women were subsequently enrolled in a
further 10-years of observational follow-up; The Perth
Longitudinal Study of Aging Women (PLSAW) registered retrospectively in the Australian New Zealand
Clinical Trials Registry (ACTRN12615000750583).
Lateral spine images were captured during bone density testing (DXA) performed at baseline visits (1998/
1999) in 1053 of the 1460 women. Cardiovascular risk factors and APOE genotypes14 were determined in 973 of
these women. After excluding dementia events (n = 15)
occurring before 80 years, 958 women were included
(Supplementary Figure 1). Baseline characteristics for the
477 women not included in this study due to missing data
are presented in Supplementary Table 1. As expected,
women who were excluded from this study (due to withdrawing/not attending the year 1 clinic visit for AAC and/
or missing covariates) were slightly older, had a higher
CVD risk score with a higher incidence of dementiarelated hospitalisations. Written informed consent was
obtained from all participants, including follow-up from
electronic health records. The Human Ethics Committee
of the University of Western Australia approved the study
protocol and consent form (05/06/004/H50). The
Human Research Ethics Committee of the Western Australian Department of Health approved the data linkage
study (#2009/24). The manuscript complies with the
STROBE reporting guidelines for observational studies.

Baseline cardiovascular risk factor assessment
All women provided their previous medical history whilst
current medications were verified by their primary health
care provider, where possible. The International
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Classification of Primary Care−Plus (ICPC-Plus) method15
was adopted, enabling aggregation of different terms for
similar pathologic entities as defined by the ICD-10 coding
system. Information was used to determine prevalent diabetes (T89001-90009) and atherosclerotic vascular disease
(ASVD). Prevalent ASVD included coronary heart disease
(ICD-9-CM codes 410-414); heart failure (ICD-9-CM code
428); cerebrovascular disease excluding haemorrhage
(ICD-9-CM codes 433-438); and peripheral arterial disease
(ICD-9-CM codes 440-444).16 Cardiovascular medications
included antihypertensives, statins and low dose aspirin.
Former/current smoker was defined as smoking >1 cigarette/d for >3 months at any time during the participants' life.
Weight was assessed using digital scales with participants.
Height was assessed using a stadiometer and the body
mass index (BMI) was calculated in kg/m2. Blood pressure
was measured (average of three measurements) on the
right arm with a mercury column manometer with participants seated upright and rested for five minutes. Mean
arterial pressure was calculated using the following equation= [(2 x diastolic blood pressure) + systolic blood pressure]/3. Renal function measurements were available in
867/958 (90.5%) of the older adult women with estimated
glomerular filtration (eGFR) rate calculated using the
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation using serum creatinine.16 Genetyping
for APOE was performed by Polymerase Chain Reaction
(PCR) amplification17 with oligonucleotide primers.18 Alcohol intake was obtained from a questionnaire (none, <10
standard drinks p/w or ≥10 standard drinks p/w). The 10year estimated Framingham General Cardiovascular Risk
Scores (FRS) was calculated using BMI and included age,
sex, previous diabetes, smoking status and systolic blood
pressure.19

Abdominal aortic calciﬁcation 24 scores (AAC24)
Lateral spine images were collected in a convenience
sample subgroup of the original cohort in 1998 (baseline), then the majority women had LSI (82%) captured
in 1999 (Year 1). All AAC scores from 0 to 24 were
derived from digitally enhanced DXA-derived lateral single-energy images of the thoraco-lumbar spine (Hologic
4500A, Marlborough, MA, USA). A single experienced
investigator (JTS) read all images using an established
technique 20 blinded to outcomes. For studies of DXAderived images, the reported intra-rater reliability for
AAC-24 readings have been very high (intraclass correlation coefficient: 0.91 to 0.95).21 AAC24 scoring system
records AAC relative to each vertebral height (L1−L4); 0
(no calcification), 1 (≤1/3 of the aortic wall), 2 (>1/3 to
≤2/3 of the aortic wall) or 3 (>2/3 of the aortic wall) for
both the anterior and posterior aortic walls, giving a
maximum possible score of up to 24. More than 99.5%
of the images were of sufficient quality to assess AAC.
Extent of AAC24 was categorized using published
groupings of AAC (from DXA) testing the association

3
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with asymptomatic and clinical cardiovascular disease
outcomes7,22,23; low (AAC24 score 0 or 1), moderate
(AAC24 score 2−5) and extensive (AAC24 score ≥6).

Late-life dementia outcomes
Dementia outcomes over 14.5- years were tracked
through the Western Australian Data Linkage System
(Department of Health Western Australia) and retrieved
from the Western Australia Hospital Morbidity Data
Collection (HMDC). Records were obtained for each
individual from 1998 until 2013. Codes were identified
using the International Classification of Diseases, Injuries and Causes of Death Clinical Modification (ICD-9CM) or the International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Australian Modification (ICD-10-AM).24,25 The primary
outcome of the study was late-life (after the age of 80
years) dementia events (hospitalisation and/or death) as
a previous study found including death data improved
identification of those with dementia.26 Dementia codes
included; Alzheimer’s disease (ICD-9-CM 331.0, ICD10-AM F00, G30), vascular dementias (ICD-9-CM
290.4, ICD-10-AM F01) and unspecified dementias
(F03)27; also considered individually as secondary outcomes. Events were defined using the principal or additional discharge diagnosis codes from hospital
morbidity data collection. To increase identification of
dementia cases we used the linked coded multiple
causes of death data (dementia codes as above) or Parts
1 and 2 of the death certificate where coded cause of
death data was not yet available.28 Studies have used
this methodology to investigate the aetiology and consequences of dementia.28

Statistical analysis
The association between AAC categories with dementia
hospitalisation and/or death over 14.5- years was
assessed in unadjusted and multivariable-adjusted Cox
regression analyses. For the primary analyses, we
treated non-dementia deaths as censored. This approach
means that the HRs can be interpreted as the risk of
dementia for any time during follow-up assuming that
a woman stays alive for that long. Given the advanced
age of these women we also performed competing-risks
analyses based on Fine and Gray’s proportional subhazards model29 to account for the competing risk of nondementia mortality. Proportional hazards assumptions
were tested via Schoenfeld residuals. P-values of >0.05
were recorded for all analysis indicating proportional
hazards assumptions were not violated. The multivariable adjusted model included treatment code (calcium
or placebo), the FRS, cardiovascular medications (statins and low dose aspirin), prevalent ASVD, APOE genotypes (ℇ2/3, ℇ2/4, ℇ3/3, ℇ3/4, ℇ4/4) and alcohol intake
(none, <10 standard drinks p/w or ≥10 standard drinks

4

p/w). Kaplan−Meier survival curves were analysed to
identify group differences in AAC categories with
respect to time to late-life dementia hospitalisation
and/or death. The prognostic utility of the extent of
AAC over APOE genotype and CVD estimated risk
and medications was assessed using standard tests
to measure discrimination such as receiver operator
characteristics (ROC), net risk reclassification
improvement (NRI) and integrated discrimination
improvement (IDI). P-values <0.05 in two-tailed testing were considered statistically significant for primary outcomes. All analyses were undertaken using
IBM SPSS Statistics Version 25 (2012, Armonk, NY:
IBM Corp) and STATA Version 13 (StataCorp LP,
College Station, TX).

Additional analysis
We undertook analysis replacing estimated CVD risk
with the individual variables used to derive the estimated Framingham risk score (age, BMI, previous diabetes, smoking history and systolic blood pressure) to
the multivariable-adjusted model. We also included
eGFR as a covariate to the multivariable-adjusted model
due to its potential link to vascular calcification and/or
dementia. We examined the relationship between AAC
and any dementia event where we excluded women
with incident haemorrhagic or ischemic strokes (I60
−I69) prior to dementia events; given such events are
also associated with greater risk of dementia. As carriage of the APOE ℇ4 allele is known to be associated
with increased risk of dementia,30 the relationship
between AAC and dementia events in individuals with
or without the presence of the APOE ℇ4 allele was investigated. Additionally, we dichotomised AAC and APOE
genotypes into four groups (low AAC and no APOE ℇ4
allele; low AAC and an APOE ℇ4 allele; moderate to
extensive AAC and no APOE ℇ4 allele; and moderate to
extensive AAC and an APOE ℇ4 allele) and examined its
relationship with late-life dementia events in multivariable-adjusted Cox models.

Ethical standards
All participants provided written informed consent.
Ethics approval was granted by the Human Ethics
Committee of the University of Western Australia.
CAIFOS and PLSAW studies were retrospectively
registered on the Australian New Zealand Clinical
Trials Registry (CAIFOS trial registration number
#ACTRN12615000750583 and PLSAW trial registration number #ACTRN12617000640303) and complied with the Declaration of Helsinki. Human
ethics approval for the use of linked data was provided by the Human Research Ethics Committee of
the Western Australian Department of Health (project number #2009/24).
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Role of the funding source
None of the funding agencies had any role in the conduct of the study; collection, management, analysis, or
interpretation of the data; or preparation, review, or
approval of the manuscript.

Results
Study recruitment overview is provided in Supplementary Figure 1. There were 15 women presenting with
dementia hospitalisation or death before aged 80 years
and were excluded. 150 women had a late-life dementia
hospitalisation or death (132 women with late-life
dementia hospitalisation and 58 with late-life dementia
death). Of these, 72 women had an Alzheimer’s disease
event, 109 had an unspecified dementia event and 7
had a vascular dementia event. At baseline, women who
later sustained a late-life dementia event were more
likely to be older, have a lower BMI, were less likely to
have been randomised to calcium supplementation,
have higher estimated 10-year CVD risk, and were more
likely to have an APOE ℇ4 allele (Table 1). 44.7% of
women had low AAC, 36.4% had moderate AAC and

18.9% had extensive AAC. Baseline characteristics presented by AAC extent can be found in Supplementary
Table 2.

AAC categories and late-life dementia
Mean § SD follow-up time for a late-life dementia hospitalisation (total person years 12,089) and/or death
(total person years 12,381) was 12.6 § 3.0 and
12.9 § 2.9 y, respectively. Women in moderate to extensive AAC groups had greater cumulative event rates in
Kaplan−Meier curves for hospitalisations at around 67 years, and deaths at around 9-10 years (Figure 1). After
multivariable-adjustment, women with moderate AAC
were at a 2- and 3-fold increased relative hazard of latelife dementia hospitalisations or deaths compared to
those with low AAC (Table 2). Women with extensive
AAC had a 2- and 4-fold increase in the adjusted relative
hazard of late-life dementia hospitalisation or death
(Table 2). When investigating the types of dementia,
women with moderate to extensive AAC were at a 2-fold
increased relative hazard of late-life AD and unspecified
dementia hospitalisations or deaths compared to those
with low AAC, in the unadjusted and multivariable-

Late-life dementia

P-value

Whole cohort

No late-life dementia

Number

958

808

150

Age, years

75.0 § 2.6

74.8 § 2.5

76.0 § 2.8

<0.001

Body mass index, kg/m2

27.1 § 4.4

27.3 § 4.5

26.4 § 4.0

0.021

Ever smoked, yes (%)

340 (35.5)

271 (33.5)

69 (46.0)

0.003

Systolic blood pressure, mmHg

137.4 § 18.0

137.2 § 17.2

138.4 § 22.1

0.463

Antihypertensive medication, yes (%)

403 (42.1)

339 (42.0)

64 (42.7)

0.871

Diabetes, yes (%)

57 (5.9)

41 (5.1)

16 (10.7)

0.008

Estimated CVD risk (Framingham), %

21.8 § 10.7

21.4 § 10.1

24.0 § 13.5

0.006

Statins medication, yes (%)

182 (19.1)

154 (19.1)

28 (18.7)

0.910

Low dose aspirin, yes (%)

189 (19.7)

152 (18.8)

37 (24.7)

0.098

Previous ASVD, yes (%)

105 (11.0)

88 (10.9)

17 (11.3)

Alcohol
None (%)

171 (17.8)

141 (17.5)

30 (20.0)

<10 standard drinks p/w (%)

631 (65.9)

535 (66.2)

96 (64.0)

≥10 standard drinks p/w (%)

156 (16.3)

132 (16.3)

24 (16.0)

465 (48.5)

404 (50.0)

61 (40.7)

Randomisation, calcium (%)

0.873
0.754

APOE genotypes

0.036
<0.001

APOE ℇ2/3, yes (%)

160 (16.7)

145 (17.9)

15 (10.0)

APOE ℇ2/4, yes (%)

18 (1.9)

16 (2.0)

2 (1.3)

APOE ℇ3/3, yes (%)

581 (60.6)

496 (61.4)

85 (56.7)

APOE ℇ3/4, yes (%)

186 (19.4)

146 (18.1)

40 (26.7)

APOE ℇ4/4, yes (%)

13 (1.4)

5 (0.6)

8 (5.3)

Low (AAC24 0 or 1)

428 (44.7)

384 (47.5)

44 (29.3)

Moderate (AAC24 2−5)

349 (36.4)

277 (34.3)

72 (48.0)

Extensive (AAC24 ≥6)

181 (18.9)

147 (18.2)

34 (22.7)

<0.001

Abdominal aortic calciﬁcation

Table 1: Baseline characteristics of the study population stratiﬁed by development of late-life dementia.
Data expressed as mean § SD or number and (%). Abbreviations: mmHg, millimetres mercury; ASVD, atherosclerotic vascular disease; APOE, apolipoprotein
E. P-values obtained using ANOVA or Chi Square test where appropriate.
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Figure 1. Kaplan Meier Survival curves for late-life dementia (A) hospitalisations and (B) deaths by severity of abdominal aortic calciﬁcation (AAC) categories. Black line- low AAC, grey linemoderate AAC and mustard line- extensive AAC.
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adjusted model (Supplementary Table 3). Due to only 7
women having vascular dementia (1 with low AAC, 5
with moderate AAC and 1 with extensive AAC) no further analyses of this outcome was undertaken.
The addition of the AAC categories to models
accounting for estimated cardiovascular risk, cardiovascular medications, alcohol intake and APOE genotype
led to improvements in the area under the curve for
late-life dementia deaths and events (Table 3). Categoryfree net reclassification improvements indicated the
addition of AAC led to 33−49% being correctly reclassified, predominantly women who suffered a dementia
hospitalisation or death being correctly moved up in
risk. The Hosmer-Lemeshow test (p = 0.842) also indicated that our models analyzing the relationship
between AAC and any dementia-related event was well
calibrated (Supplementary Figure 2).

Additional analyses
Including individual variables used to compute FRS to
the multivariable-adjusted model did not alter the relationship between AAC categories, dementia-related
events and deaths (Supplementary Table 4). For dementia-related hospitalisations, this relationship was slightly
attenuated for women with extensive AAC (p = 0.056).
Competing risks analyses for non-dementia deaths did
not substantially affect the point estimates for the AAC
groups (Supplementary Table 5). Including eGFR to the
multivariable-adjusted Cox model also did not result in
substantive changes to the observed associations
between AAC and late-life dementia events (Supplementary Table 6). Point estimates for the relationship
between AAC categories (moderate AAC HR 2.06
95%CI 1.35−3.15, p < 0.001; extensive AAC HR 2.31
95%CI 1.39−3.83, p < 0.001) and all dementia events
remained similar when we excluded women with incident haemorrhagic or ischemic CVAs (n = 125). In
women who did not carry an APOE ℇ4 allele (n = 741),
those with moderate AAC (n = 265, HR 2.36 95%CI
1.48−3.75, p < 0.001) and extensive AAC (n = 142, HR
2.07 95%CI 1.17−3.64, p = 0.012) had greater risk for
any dementia-related event, compared to women with
low AAC (n = 334). However, in women carrying an
APOE ℇ4 allele (n = 217), AAC status was not associated
with significantly increased dementia-related events
despite similar aHRs. Here, compared to women with
low AAC (n = 94), those with moderate AAC (n = 84)
and extensive AAC (n = 39) had HR’s for dementiarelated events of 1.81 95%CI 0.93−3.53, p = 0.081 and
1.89 95%CI 0.85−4.17, p = 0.115 respectively. Finally, in
a multivariable-adjusted analysis, compared to women
with low AAC and no APOE ℇ4 allele, those with low
AAC and an APOE ℇ4 allele (n = 94), moderate to extensive AAC and no APOE ℇ4 allele (n = 407), and moderate to extensive AAC and a APOE ℇ4 allele had 207%,
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Multivariable-adjusted HR (95% CI)#

Number (%)

Unadjusted HR (95% CI)

Low AAC (AAC24 score 0 or 1)

44 (10.3)

1 (reference)

1 (reference)

Moderate AAC (AAC24 score 2−5)

72 (22.6)

2.19 (1.51−3.19)*

2.03 (1.38−2.97)*

Extensive AAC (AAC24 score ≥6)

34 (18.8)

Any late-life dementia event

P for trend

2.06 (1.32−3.22)*

2.10 (1.33−3.32)*

0.001

0.001

Any late-life dementia hospitalisation
Low AAC (AAC24 score 0 or 1)

40 (9.3)

1 (reference)

1 (reference)

Moderate AAC (AAC24 score 2−5)

64 (18.3)

2.14 (1.44−3.17)*

1.95 (1.30−2.91)*

Extensive AAC (AAC24 score ≥6)

28 (15.5)

P for trend

1.86 (1.15−3.01)*

1.92 (1.17−3.15)*

0.008

0.006

Any late-life dementia death
Low AAC (AAC24 score 0 or 1)

12 (2.8)

1 (reference)

1 (reference)

Moderate AAC (AAC24 score 2−5)

29 (8.3)

3.18 (1.62−6.24)*

3.09 (1.56−6.10)*

Extensive AAC (AAC24 score ≥6)

17 (9.4)

P for trend

3.78 (1.80−7.91)*

3.88 (1.82−8.28)*

<0.001

<0.001

Table 2: Cox proportional hazards regression for late-life dementia events by extent of abdominal aortic calciﬁcation.
Abbreviations: AAC; abdominal aortic calcification, ASVD; atherosclerotic vascular disease, HR; hazard ratio.
#
Cox proportional hazards regression analyses were adjusted for General Framingham Risk Score plus treatment code (calcium or placebo), alcohol intake,
prevalent ASVD, prescription of statin medications, use of low dose aspirin and Apolipoprotein E genotype. Trend test performed using the median values for
each AAC severity category.
* indicates p-values<0.05 compared to women with no-low abdominal aortic calcification.

221% and 412% greater relative hazards for any late-life
dementia event (Figure 2).

Discussion
To our knowledge this is the first study to report an
association between AAC and the risk of future late-life
dementia. In older women at high risk of late-life
dementia, widely available bone density machines may
be an novel inexpensive, safe, and non-invasive way to
identify individuals with accumulated vascular damage
at substantively higher risk of dementia hospitalisations
and deaths. Specifically, we demonstrated that over half

AUC

of the older women with AAC were at 2 to 4 times the
risk of late-life dementia hospitalisation and deaths over
the next 15- years. Importantly, both extent of AAC and
APOE ℇ4 genotype provided complimentary prognostic
information in older women suggesting this may be
novel way to identify high risk older women. Given
recent advances in the automation of AAC this offers a
cheap, rapid and safe way to screen for late-life dementia risk. Noteworthy, the addition of AAC to estimated
CVD risk, medication and APOE ℇ4 genotype demonstrated improved discrimination for predicting these
late-life dementia events in addition to these established
risk factors. These findings suggest that a combination

p- value#

Category-free
NRI

Net events correctly r
eclassiﬁed higher

Net non-events correctly r
eclassiﬁed lower

IDI, p-value

0.018

0.383

30.7%

7.7%

0.011, p = 0.006

0.056

0.366

30.3%

6.3%

0.007, p = 0.029

0.014

0.492

41.4%

7.8%

0.013, p = 0.007

Late-life dementia, (n = 150)
Full model

0.635

Full model + AAC severity

0.678*

Late-life dementia hospitalisations, (n = 132)
Full model

0.667

Full model + AAC severity

0.697

Dementia deaths, (n = 58)
Full model

0.631

Full model + AAC severity

0.711*

Table 3: Analyses of the area under the curve, net reclassiﬁcation improvement and integrated discrimination indices.
Abbreviations: AAC; abdominal aortic calcification, ASVD; atherosclerotic vascular disease, AUC; area under the curve, IDI; integrated discrimination indices,
NRI; net reclassification improvement. #Compared to full model were including General Framingham Risk Score plus treatment code (calcium or placebo),
alcohol intake, prevalent ASVD, prescription of statin medications, use of low dose aspirin and APOE genotype.
* significantly different from full model.
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Figure 2. Multivariable-adjusted Cox regression for late-life dementia events (hospitalisation and/or death) dichotomised by severity
of abdominal aortic calciﬁcation (AAC) and the presence of the APOE ℇ4 gene.

of genetics and vascular imaging can identify a high-risk
population where implementation of lifestyle31 and/or
pharmaceutical32 disease modifying interventions has
the potential to prevent late-life dementia.
While findings that cardiovascular risk measures are
associated with dementia risk are not new, the gradients
of risk observed in this study across the AAC categories
warrant particular attention with over 55% of the
women being at 2−4 times the risk of late-life dementia.
When compared to coronary artery calcification these
gradients of risk are substantially higher. For example,
Akira and colleagues found that in the 6293 participants of the Multi-Ethnic Study of Atherosclerosis (free
of cardiovascular disease and noticeable cognitive deficit) that the adjusted HR were 1.23 for people with CAC
scores of 1−400, 1.35 for those with CAC scores 400
−1000 and 1.71 for those with CAC scores >1000.
Results were attenuated for all groups except CAC
>1000 when interim strokes were excluded.33 Other
also report that coronary artery calcification was not
associated with dementia risk. However, in minimally
adjusted models, aortic arch calcification, intracranial
carotid calcification and extracranial carotid calcification were associated and only extracranial carotid calcification remained significant after adjusting for
APOE ℇ4 genotype and cardiovascular risk factors.34
A recent systematic review and meta-analysis also
found that pooled HR of clinical coronary artery disease with incident mild cognitive impairment or
dementia in six studies (n = 70,060 individuals) was
1.51.35 Similar, modest increases in dementia risk are
seen with carotid ultrasound measures of
atherosclerosis.36,37 Collectively, these findings suggests that AAC may be a better marker of future
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dementia risk than measures of coronary or carotid
atherosclerosis.
Presumably this may be due to AAC being more
strongly related to increasing aortic stiffness8,38 and
raised central blood pressure.39 Alternative explanations
include that AAC is thought to precede CAC40 and has
been shown to be an independent predictor of CAC incidence and long-term progression.41; Interestingly the
Multiethnic Study of Atherosclerosis found AAC and
CAC predicted hard coronary heart disease and hard
CVD independent of risk factors and one another,
whilst only AAC was independently associated with
CVD mortality and was more strongly associated with
all-cause mortality.42 Whilst traditional cardiovascular
risk factors such as lipids and blood pressure are related
to the development and progression of both CAC and
AAC,41 the progression of AAC has also been shown to
be associated with non-traditional CVD risk factors such
as chronic kidney disease,43 rapid bone loss44 and low
muscle mass and poor physical function.45 These conditions have all been shown to be associated with
increased risk of cognitive deficits or decline.46−48
Taken together these studies suggest AAC, may be an
early marker of systemic atherosclerotic vascular disease
burden and capture non-traditional cardiovascular disease risk factors compared to CAC. Hence AAC is likely
to add new information on the risk of late-life dementia
compared to CAC alone. However, future studies
directly comparing AAC and CAC with late-life dementia events are needed.
Early diagnosis and the implementation of intervention strategies to reduce risk factors are likely to reduce
the burden of dementia.49 Previous research assessing
both AAC and coronary artery calcification (CAC) have
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often relied on the use of CT scanning which limits the
clinical utility of these measurements due to cost and
patient radiation exposure.50,51 Our results demonstrate
that extensive AAC, assessed on low radiation DXAderived LSI are robustly associated with greater relative
hazard of dementia hospitalisations and deaths. There
is currently great interest in the automation of AAC
assessment which would enhance its clinical utility.52
While this is the first study to investigate the relationship between AAC and late-life dementia risk over 14.5years, previous studies have assessed the association
between AAC with cognition and markers of brain
health. Reis, Launer53 investigated the relationship
between cognition and computed tomography (CT) generated AAC. An inverse relationship between AAC and
measures of verbal learning and processing speed were
recorded.53 Noteworthy, verbal memory (Rey Auditory
Verbal Learning Test) is reported to be sensitive to the
early markers of cognitive decline that characterise
dementia and AD.54 Similarly, the Rotterdam study
reported that mid-life (»55 years of age) assessment of
AAC was predictive of MRI determined white matter
periventricular lesion burden detected 20- years subsequent to initial assessment, but not in those with MRI
assessments only 5- years post initial AAC assessment.55
A cross sectional study of 1209 individuals (≥60 years)
also reported that DXA assessed AAC was associated
with poorer performance in global cognition, verbal
memory, and language fluency.56 However, stratification by age (<75 years, ≥75 years) showed that AAC and
cognition was only identified in individuals 60
−75 years.56
These clinical findings from previous studies are in
general supportive of the current findings. There
appears to be a delay of about 5- years between the AAC
measurement and the onset of clinical disease of a
severity resulting in hospitalisation or death. Future
work evaluating changes in neurophysiology during
this time will hopefully contribute to interventions to
prevent progression. In this regard, it should be noted
that in this study participants with severe AAC at
increased dementia risk were receiving similar exposure
to cardiovascular disease medications as those who did
not develop dementia. Perhaps, they would have
benefited from more aggressive treatment based on
their AAC score.
Mechanistically, in older individuals with dementia,
cerebrovascular changes are a common neuropathologic
feature. Some neuropathologic features of dementia
include endothelial dysfunction, atherosclerosis, ischemia, haemorrhage and cerebral amyloid angiopathy.57
When considering cerebrovascular risk factors, there
appears to be a relationship with neuropathologic correlates of dementia. For example, metabolic disease
(hypertension, diabetes, hypercholesterolemia), smoking, and aging are all risk factors for vascular disease
and the risk for AD-related dementias. Specifically,
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neuropathology may be impacted by hypoxia (caused by
haemorrhage and ischemia), metabolic dysfunction
(decreases glucose metabolism and mitochondrial function) and cerebrovascular haemodynamics (endothelial
damage, higher blood pressure and tortuosity) (see57 for
review). Noteworthy, AAC is associated with stiffening
of blood vessels that can increase pressure transmitted
into small vessels in other organs such as the brain that
can lead to end-organ damage.8 As such, increased central blood pressure may increase dementia risk.58 Our
results could also be due to the overlapping pathologies
for which AAC is a marker of, and which are themselves
risk factors for dementia and AD. It is particularly noteworthy, that CAC has also been linked smaller total
brain volume59 and increased atrophy,60 increased
white matter infarcts61 and lesions.50,59 Collectively, atherosclerotic calcification is likely to be a strong contributor towards the neuropathologic features of dementia
and supports further investigation of subclinical measures of abdominal aortic calcification for disease risk
stratification during aging. Regarding the presence of
APOE ℇ4 allele, our findings were similar to previous
epidemiological work30 identifying the important role
for this genotype for increased risk of late life dementia.
Further, it evidenced that that an increased AAC score
is additional to genotype, being an equally important
risk factor for late-life dementia.
Strengths of this study include the use of DXAderived LSI for AAC measurement assessed by a highly
experienced investigator (JTS) blinded to clinical data.
This work considered a wealth of comorbidity and covariate information for inclusion in each analysis, including CVD risk factors, medications, and APOE
genotyping. We have also demonstrated that the degree
of AAC was a strong contributor in addition to other cardiovascular and dementia associated covariates in our
multivariable-adjusted model. The use of high-quality
objective administrative data from two sources with an
18-year lookback period and 15- years of follow up,
reduce the risk of selection and misclassification bias.
Adopting ICD coding, based on clinical diagnosis, for
the categorisation of dementia outcomes also reduces
potential bias in dementia diagnosis. Nevertheless, this
study has limitations. The major limitation is the reliance on linked Hospital discharge administrative data
which has been shown to have high accuracy (96.7%)
but low sensitivity (21.2%) compared to chart review;
although adding this data increases dementia ascertainment compared to death certificates alone.28 In other
Australian administrative data, the ICD-10 dementia
diagnoses from hospital records has been shown substantial agreement (k = 0.71) with a sensitivity of 67%
and a positive predictive value of 76%.62 In the current
study the 15-year incidence in these older women was
15.7% which is similar to the incidence reported in the
Australian Longitudinal Study on Women’s Health.
This study followed women aged 70 years or older in
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1996 and investigated multiple administrative data
sources to identify dementia cases including aged care
assessments data, hospital admissions data for three
states (Queensland, New South Wales, and South Australia), pharmaceutical data, death records and selfreported survey data (six surveys which occurred at 3year intervals). Over the 16- years of follow-up, 20.4% of
women were identified as having dementia in at least
one of the data sources with aged care data identifying
the most cases (79.3%), followed by hospital admission
data (55.8%), pharmaceutical records (34.6%), death
records (31.0%) and self-reported survey data with
18.5%.63 Importantly, if dementia diagnosis was missed,
this would have biased the results towards the null.
Additionally, due to the observational nature of our
study, causality cannot be established. Another potential
limitation is that the AAC observed may be due to nonatherosclerotic processes i.e. medial calcifications or a
combination atherosclerotic and medial calcification as
the localisation and underlying pathophysiology of the
calcifications of the abdominal aorta is poorly understood. This is due to limited histological studies and current conventional imaging methodologies not being
able to localise calcification within the different layers of
the arterial wall.64 Despite considering a range of cardiovascular and dementia-related risk factors, there is
the potential for residual confounding. DXA generated
images for the quantification of AAC were only captured
in 70% of the original cohort, potentially biasing results.
As AAC was assessed in women ≥70 year who were
healthy ambulant community-dwelling older women
not on bone active medications, we cannot exclude the
risk of selection bias. Of note, the prevalence of women
with the APOE ℇ4 genotype in our study was 23%,
which is similar to the 22−28% of individuals presenting with at least one APOE ℇ4 allele in other cohorts
from Australia.65,66 Furthermore, as AAC was assessed
in women ≥70 years, this could be on the fringe as an
ideal pre-clinical dementia screening tool for early intervention.1 We had limited power to examine the associations of AAC for specific types of dementia. Finally,
findings may not be generalised to younger women or
men. Consequently, it will be important to replicate
these findings in other cohorts.
In conclusion, this study identified an association
between AAC and the subsequent development of latelife dementia. Significant increases in risk for hospitalisation and death from dementia were observed with
increasing severity of AAC, in addition to shorter times
to each of these events. Several proposed mechanisms
and pathways which are impacted by an individual’s cardiovascular risk profile likely contribute to the relationship between AAC and dementia. Therefore,
understanding the impact of shared risk factors could
allow for targeted disease modifying strategies. To this
end, lateral spine imaging to detect AAC as well as spine
fractures during bone density scanning, has potential

10

for use as an early screening and assessment tool to
identify women at higher risk of dementia, allowing for
the implementation of early lifestyle intervention strategies in at risk populations. Such studies should be a
high priority for long-term randomised controlled trials.
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